Eli Lilly (LLY) Moves Fast to Secure Lead in India’s Obesity Drug Market

Core Insights - Eli Lilly and Company is rapidly establishing its presence in India's obesity drug market, which is expected to grow significantly due to the anticipated arrival of cheaper generic versions [2][3] - The global obesity drug market is projected to reach $150 billion annually by the end of the decade, making it a critical area for pharmaceutical companies [3] - Eli Lilly's Mounjaro has quickly become the top-selling therapy in India for both diabetes and weight loss, with sales doubling shortly after its launch [4] Company Strategy - Eli Lilly is focusing on building brand loyalty in India through partnerships with Bollywood actors for a social media campaign aimed at obesity awareness [2] - The company is also adjusting its pricing strategy, having reduced prices for its diabetes and weight-loss drugs in Canada and the US to enhance accessibility for patients [5] Market Position - By October, Mounjaro had surpassed Novo's Wegovy in sales value in India, indicating strong market momentum as competition intensifies [4] - Eli Lilly operates as a global pharmaceutical firm with a focus on major health challenges, including diabetes, oncology, immunology, and neuroscience, with an increasing emphasis on weight-loss and metabolic treatments [6]